CJC-1295 and ipamorelin are peptides sometimes marketed online for growth hormone signaling, recovery, sleep, or body composition. They are not FDA-approved drugs for these uses, and access should involve a licensed clinician, eligibility review, and a clear discussion of evidence limits, risks, pharmacy sourcing, and legal availability.
Wondering if sermorelin is right for you? Take the 3-min clinical quiz.
See if you qualify →Can you get CJC-1295 and ipamorelin prescribed online?
In some settings, patients look for CJC-1295 and ipamorelin through online peptide clinics, but the important question is not just whether a website sells them. The safer question is whether a licensed clinician reviews eligibility, explains risks, and uses a legitimate pharmacy pathway.
CJC-1295 and ipamorelin are not FDA-approved drugs for wellness, recovery, sleep, body composition, or longevity. FDA explains that compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing 1.
What an online peptide prescription should involve
A responsible online pathway should feel like medical care, not checkout. It should include a health history, medication review, goal review, contraindication screen, state-specific eligibility check, and follow-up plan. For hormones and growth hormone signaling, clinician monitoring matters because the same pathways that affect biomarkers can also affect glucose, fluid balance, sleep apnea risk, and symptoms such as swelling or joint discomfort 2.
Why a prescription is not guaranteed
A prescription is a clinical decision. A clinician may decide that a peptide is not appropriate because of a medical history, current medications, lab concerns, pregnancy or breastfeeding, cancer history, endocrine disease, or unclear benefit for the patient’s goal. This is normal and is part of safe prescribing.
Red flags when buying peptides online
- A website sells “research-use-only” peptides while giving human-use instructions.
- No licensed clinician reviews your health history.
- There is no clear pharmacy source or state licensure information.
- The site promises fat loss, muscle gain, better sleep, or anti-aging results without citing human clinical evidence.
- There is no follow-up, patient portal, side-effect plan, or way to ask medical questions.
What are CJC-1295 and ipamorelin?
CJC-1295 and ipamorelin are peptides that influence growth hormone signaling through different receptors. They are often discussed together because one acts on the growth hormone-releasing hormone pathway and the other acts on the growth hormone secretagogue pathway.
What CJC-1295 is
CJC-1295 is a modified growth hormone-releasing hormone analog. In plain English, it is designed to interact with the growth hormone-releasing hormone receptor, a signal point that helps the pituitary gland release growth hormone. CJC-1295 with DAC includes a drug-affinity complex that binds albumin and extends exposure time in the body; in a human study, one injection led to growth hormone and IGF-1 increases that lasted several days 3.
What ipamorelin is
Ipamorelin is a growth hormone secretagogue and ghrelin receptor agonist. It acts at the growth hormone secretagogue receptor, which can stimulate growth hormone pulses. Early research found that ipamorelin increased growth hormone in animal and human pharmacology models while having less effect on some other pituitary hormones than older growth hormone secretagogues 4.
Why these peptides are often paired
They are often paired because they act on related but different growth hormone signaling pathways. The theory is that a growth hormone-releasing hormone analog and a growth hormone secretagogue may give complementary signals to the pituitary. That theory should not be treated as proof of clinical outcomes. Combination-specific human trials for wellness, body composition, sleep, recovery, or longevity are limited.
How growth hormone signaling differs from taking growth hormone
Growth hormone secretagogues ask the pituitary to release growth hormone. Recombinant human growth hormone provides growth hormone directly. Endocrine Society guidance for adult growth hormone deficiency focuses on diagnosed deficiency, careful selection, and monitoring because growth hormone therapy can cause side effects such as fluid retention, joint symptoms, carpal tunnel symptoms, and changes in glucose metabolism 2.
What does the evidence say about CJC-1295 and ipamorelin?
The honest evidence summary is narrow: small studies show biomarker effects, not proven wellness outcomes. Growth hormone and insulin-like growth factor 1, or IGF-1, can change after some secretagogue peptides, but biomarkers do not guarantee fat loss, muscle gain, better sleep, faster recovery, or longer life.
Human evidence for growth hormone and IGF-1 biomarker changes
In a randomized study of healthy adults, Teichman and colleagues reported that CJC-1295 increased mean growth hormone and IGF-1 levels after single and multiple injections, with effects lasting up to several days depending on the dose studied 3. This is useful mechanistic evidence, but it was not a long-term outcomes trial for body composition, recovery, sleep, or longevity.
Ipamorelin has also been studied as a growth hormone secretagogue. Raun and colleagues reported growth hormone release after ipamorelin exposure in early pharmacology work, including animal models and human volunteer data, but this type of evidence is not the same as showing durable patient-centered results 4.
What the research does not prove about fat loss, muscle gain, sleep, or longevity
For CJC-1295/ipamorelin, the evidence does not prove predictable fat loss, muscle gain, better sleep, faster injury recovery, or human life extension. Those claims would require well-designed human trials that measure those outcomes directly, track side effects, and compare results with placebo or standard care. Individual results vary, and biomarker changes should not be read as a promise.
Why biomarker changes should not be treated as guaranteed outcomes
IGF-1 and growth hormone are signals, not final outcomes. Higher or lower values can mean different things depending on age, sex, sleep, nutrition, training, medical conditions, and medications. Growth hormone–axis therapies can also cause adverse effects, so any potential benefit must be weighed against risk in the same clinical visit 2.
Is CJC-1295 and ipamorelin peptide therapy FDA approved?
CJC-1295 and ipamorelin are not FDA-approved for wellness, recovery, sleep, performance, body composition, or longevity. FDA approval means a specific drug product was reviewed for a specific use, dose range, labeling, manufacturing controls, and risk-benefit profile.
FDA approval versus compounded prescribing
FDA approval and compounding are different pathways. FDA-approved drugs go through FDA review before marketing. Compounded drugs are made for an individual patient under a prescriber’s order when legal requirements are met, but they are not FDA-approved 1.
What 503A compounding means
A 503A compounding pharmacy is a state-licensed pharmacy that compounds medications for identified individual patients based on prescriptions. Section 503A of the Federal Food, Drug, and Cosmetic Act describes conditions under which certain compounded human drug products may qualify for exemptions from some federal requirements 5.
Why compounded medications are not FDA-approved
FDA states that compounded drugs can serve an important role for patients whose needs cannot be met by an FDA-approved drug, but FDA does not verify compounded drugs for safety, effectiveness, or quality before they are marketed 1. That is why pharmacy legitimacy, clinician review, and follow-up are central safety checks.
Who should be cautious about growth hormone secretagogue peptides?
Growth hormone secretagogue peptides may not be appropriate for some people. A clinician should review medical history, medications, symptoms, and goals before deciding whether any growth hormone–axis therapy makes sense.
Medical history a clinician may review
- History of cancer or unexplained masses, because growth hormone and IGF-1 signaling can be clinically relevant in growth-related pathways.
- Diabetes, prediabetes, or insulin resistance, because growth hormone can affect glucose metabolism 2.
- Sleep apnea, swelling, carpal tunnel symptoms, or joint pain, because growth hormone therapy can worsen fluid-related symptoms in some patients 2.
- Pituitary disease, thyroid disease, adrenal disease, or abnormal IGF-1 labs.
- Pregnancy, breastfeeding, or plans to become pregnant.
- Use of medications that affect glucose, hormones, or fluid balance.
Potential side effects and monitoring questions
Possible concerns include injection-site reactions, headache, flushing, water retention, tingling, joint discomfort, carpal tunnel symptoms, and glucose changes. The exact risk profile depends on the compound, route, dose studied, patient history, and whether the product is made and monitored through a legitimate medical pathway.
When a clinician may recommend another path
A clinician may recommend lifestyle care, sleep evaluation, nutrition changes, strength training, labs, treatment of an endocrine condition, or a different medication pathway. That does not mean your goals are not valid. It means the benefit-risk picture may point somewhere else.
CJC-1295 and ipamorelin vs sermorelin: how do they compare?
Sermorelin acetate is also a growth hormone-releasing hormone analog, but it is not the same compound as CJC-1295 or ipamorelin. They overlap in the growth hormone axis, yet differ in structure, receptor activity, evidence base, and availability through legitimate prescription pathways.
| Peptide | What it is | Main signaling pathway | Evidence snapshot | Chia availability |
|---|---|---|---|---|
| CJC-1295 | Modified growth hormone-releasing hormone analog; CJC-1295 with DAC was designed for longer exposure | Growth hormone-releasing hormone receptor | Small human studies show growth hormone and IGF-1 biomarker changes, not proven wellness outcomes 3 | Not currently listed in Chia’s public treatment catalog |
| Ipamorelin | Growth hormone secretagogue and ghrelin receptor agonist | Growth hormone secretagogue receptor | Early pharmacology evidence shows growth hormone release; patient-centered outcome data are limited 4 | Not currently listed in Chia’s public treatment catalog |
| Sermorelin | Growth hormone-releasing hormone analog also known as sermorelin acetate | Growth hormone-releasing hormone receptor | Studied for growth hormone stimulation and historically used in diagnostic contexts; wellness outcomes are not guaranteed 6 | Available at Chia as injection, nasal spray, and tablets |
Mechanism comparison
CJC-1295 and sermorelin both relate to the growth hormone-releasing hormone receptor. Ipamorelin works through the growth hormone secretagogue receptor, a different signal point. This is why CJC-1295 and ipamorelin are often discussed as a pair, while sermorelin is usually discussed as its own growth hormone-releasing hormone analog.
Evidence and regulatory differences
The best-supported statement for these peptides is that they can affect growth hormone signaling. That does not prove a specific body composition, sleep, performance, or longevity result. For any compounded peptide, clinical expectations should stay modest unless there are direct human outcome trials for that exact use.
Availability through legitimate prescription pathways
Availability changes by compound, state rules, pharmacy policy, and clinician judgment. Chia’s current public catalog includes sermorelin, but not CJC-1295 or ipamorelin. We do not describe sermorelin as interchangeable with those peptides.
3-min quiz
Explore clinician-reviewed sermorelin care
Chia does not currently offer CJC-1295 or ipamorelin. If your goals relate to growth hormone signaling, our providers can review whether sermorelin is appropriate for you. A prescription requires a medical evaluation and is not guaranteed. Compounded medications are not FDA-approved.
Peptide treatment at Chia: sermorelin options and clinician-reviewed care
At Chia, we treat peptide care as medical care. Chia currently offers sermorelin in 3 forms—injection, nasal spray, and tablets—but CJC-1295 and ipamorelin are not listed in our current public treatment catalog.
Chia does not currently offer CJC-1295 or ipamorelin
We want this to be clear: Chia does not currently list CJC-1295 or ipamorelin as available treatments. If those compounds are the only treatments you are seeking, this article is educational and should not be read as an offer to prescribe them through Chia.
Sermorelin at Chia: injection, nasal spray, or tablets
Chia offers sermorelin as an injection, nasal spray, or tablets. Sermorelin injection and nasal spray plans currently start at $179/month; readers should check the product page for current details. Dosing is provider-guided and adjusted over time when clinically appropriate.
| Chia sermorelin form | How it may fit a patient’s routine | Current starting price listed by Chia |
|---|---|---|
| Injection | For patients comfortable with an injectable peptide plan and provider-guided follow-up | From $179/month |
| Nasal spray | For patients who prefer a non-injection route when clinically appropriate | From $179/month |
| Tablets | For patients who prefer an oral option when clinically appropriate | Price not listed in the provided catalog |
Weight + Muscle at Chia: sermorelin injection plus choice of GLP-1
For patients whose goals include body composition and weight care, Chia also offers Weight + Muscle, which includes sermorelin injection plus a choice of GLP-1. Plans currently start at $329/month. This protocol is not CJC-1295/ipamorelin and should not be viewed as interchangeable.
How Chia’s online clinician review works
- 1Start with Chia’s online eligibility quiz and health questionnaire.
- 2A licensed US provider reviews your history, goals, medications, and risks.
- 3If appropriate, the provider prescribes a compounded medication through a US state-licensed 503A compounding pharmacy.
- 4Medication is shipped to your door, and your dosing plan is guided by your provider.
- 5You can message your care team through the patient portal between visits.
How should you evaluate an online peptide clinic?
A peptide clinic should make safety steps easy to see. The key check is licensed medical care, not how fast a site can ship a vial.
Licensed provider review
Look for a real clinician review before prescribing. For growth hormone–axis peptides, the clinician should ask about endocrine history, glucose issues, cancer history, sleep apnea, pregnancy status, medications, symptoms, and goals.
State-licensed 503A pharmacy sourcing
For compounded medications, pharmacy sourcing matters. FDA’s compounding materials explain that compounded drugs are not FDA-approved, which makes state licensure, prescription-only dispensing, and quality practices important parts of risk reduction 1.
Transparent eligibility and safety information
A responsible clinic should say who may not be eligible, what side effects may occur, and what monitoring may be needed. It should not promise a specific change in weight, muscle, sleep, energy, or aging.
Clear follow-up and patient portal access
Follow-up is part of treatment. Patients should know how to report side effects, ask questions, and update their care team if medications or health conditions change.
Avoiding research-use-only products sold for human use
Research-use-only products are not a substitute for prescribed medication. If a site sells peptides without a prescription while giving human-use directions, that is a major safety concern.
3-min quiz
Start with a licensed review
If you are exploring peptide care, Chia can review whether an available option such as sermorelin or the Weight + Muscle protocol fits your goals and health history. A prescription requires a licensed provider’s evaluation and is not guaranteed. Compounded medications are not FDA-approved.
Frequently asked questions
Online access depends on the compound, pharmacy pathway, prescription status, state rules, and clinician judgment. Avoid websites that sell research-use-only peptides for human use without a licensed medical review.
For a legitimate medication pathway, peptide therapy should involve a licensed clinician, eligibility review, and pharmacy dispensing when prescribed. A prescription is not guaranteed.
No. CJC-1295, ipamorelin, and sermorelin all relate to growth hormone signaling, but they are different compounds with different mechanisms and evidence limits.
No. Compounded medications are not FDA-approved, and FDA does not review compounded drugs for safety, effectiveness, or quality before marketing.
Timelines vary by peptide, goal, health history, and monitoring plan. For CJC-1295 and ipamorelin, biomarker changes in studies should not be treated as guaranteed fat loss, muscle gain, sleep improvement, or longevity results.
No. Chia does not currently list CJC-1295 or ipamorelin in its public treatment catalog.
Chia currently offers sermorelin, GHK-Cu cream, glutathione, NAD+, and PT-141, along with listed multi-treatment protocols. Sermorelin is available through Chia as injection, nasal spray, and tablets.
References
- 1.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA, 2024.
- 2.Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism, 2011.
- 3.Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of Growth Hormone-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism, 2006.
- 4.Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the First Selective Growth Hormone Secretagogue. European Journal of Endocrinology, 1998.
- 5.U.S. Food and Drug Administration. Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. FDA, 2024.
- 6.Thorner MO, Reschke J, Chitwood J, Rogol AD, Furlanetto R, Rivier J, Vale W. Acceleration of Growth in Two Children Treated with Human Pancreatic Growth Hormone-Releasing Factor. New England Journal of Medicine, 1985.
- 7.Mayo KE, Miller T, DeAlmeida V, Zheng J, Godfrey PA. The Growth-Hormone-Releasing Hormone Receptor: Signal Transduction, Gene Expression, and Physiological Function in Growth Regulation. Annals of the New York Academy of Sciences, 2000.
- 8.Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, et al. A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release. Science, 1996.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if sermorelin is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
